ViGenCell, Inc. is a South Korea-based clinical-stage biotechnology company that develops and commercializes advanced immune cell therapies and cellular immunotherapies for the treatment of oncology and intractable immune-mediated diseases. Founded in 2013 and headquartered in Seoul, South Korea, the company operates as an affiliate of Boryung. ViGenCell develops proprietary therapeutic candidates across three primary technology platforms: the ViTier platform, an antigen-specific cytotoxic T-lymphocyte technology utilized for customized cancer immunotherapies, including VT-EBV-N for Epstein-Barr virus-positive natural killer/T-cell lymphoma and VT-Tri(1)-A for acute myeloid leukemia; the ViMedier platform, a cord blood-derived myeloid suppressor cell technology engineered to suppress abnormal immune reactions, including VM-GD (VM-001) for graft-versus-host disease and VM-AD for atopic dermatitis; and the ViRanger platform, an allogeneic universal T-cell gene therapy technology designed for off-the-shelf mass production, including gamma-delta T-cell and chimeric antigen receptor constructs as well as co-developed induced pluripotent stem cell-derived CAR-NK cell therapies such as TB-420 for hepatocellular carcinoma and TB-302 for glioblastoma. In addition, the company operates an advanced biopharmaceutical Good Manufacturing Practice facility, the V-Cell Center, supporting cell processing, clinical batch manufacturing, and contract development and manufacturing capabilities. In recent developments, ViGenCell secured regulatory certification for its V-Cell Center GMP cell processing facility, establishing full-scale in-house manufacturing and supply capabilities. The company initiated patient treatments for lead candidate VT-EBV-N under South Korea's advanced regenerative medicine statutory framework for lymphoma patients in complete remission who face high relapse risks, following the presentation of four-year follow-up Phase 2 clinical data at the American Society of Clinical Oncology Annual Meeting that demonstrated a 100 percent overall survival rate and a 95 percent disease-free survival rate. ViGenCell has also expanded strategic co-development and manufacturing agreements with Therabest for iPSC-derived CAR-NK therapeutic pipelines and strengthened executive management across GMP operations and corporate business development to accelerate pipeline commercialization.